Fingolimod is an immunomodulating drug with the trade name Gilenya. Fingolimod has been approved as a treatment for multiple sclerosis because of it's success reducing the relapse rates of multiple sclerosis by over 50%. Fingolimod has serious adverse effects. Two subjects taking this drug have died, one due to a brain herpes infection, and the other due to zoster. It is unclear whether the drug was responsible for the event, but unusual two patients had such unusual deaths. Fingolimod has been associated with fatal infections, bradycardia, skin cancer and a case of hemorrhaging focal encephalitis, which is an inflammation and bleeding in the brain. Fingolimod is has also been discovered to be a therapy for arrhythmias and heart failure.